化学
结核分枝杆菌
前药
细胞内
药物发现
肺结核
突变体
体外
计算生物学
生物化学
生物
医学
病理
基因
作者
Abraham L. Moure,Gagandeep Narula,Flavia Sorrentino,Adama Bojang,Clement K. M. Tsui,Carine Sao Emani,Esther Porras-De Francisco,Beatriz King Díaz,María José Rebollo-López,Pedro Alfonso Torres-Gómez,Eva María López-Román,Isabel Camino,Patricia Casado Castro,Laura Guijarro López,Fátima Ortega,Lluís Ballell,David Barros-Aguirre,Modesto Remuiñán Blanco,Yossef Av‐Gay
标识
DOI:10.1021/acs.jmedchem.0c00003
摘要
, a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compound is a prodrug that is bioactivated by the mycobacterial enzyme MymA. A hit-expansion program including design, synthesis, and profiling of a defined set of analogues with optimized drug-like properties led to the identification of an emerging lead compound, displaying potency against intracellular bacteria in the low micromolar range, high in vitro solubility and permeability, and excellent microsomal stability.
科研通智能强力驱动
Strongly Powered by AbleSci AI